- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04576130
A Danish ICD-study in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation (DanICD)
November 8, 2023 updated by: Reza Jabbari, Rigshospitalet, Denmark
A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Coronary Artery Disease Resuscitated From Ventricular Fibrillation Who Receive Complete Revascularization
DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
1200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Reza Jabbari, MD, PhD
- Phone Number: +4535455380
- Email: reza.jabbari.02@regionh.dk
Study Contact Backup
- Name: Thomas Engstrøm, MD, PhD, DMSc
- Phone Number: +4535458444
- Email: thomas.engstroem@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark
- Recruiting
- Copenhagen University Hospital, Rigshospitalet
-
Contact:
- Reza Jabbari, MD, PhD
- Phone Number: +4535455380
- Email: reza.jabbari.02@regionh.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.
- Age ≥18 years
- LVEF >35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.
Exclusion Criteria:
- Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)
- Previous CABG within the last 3 months before index hospitalization
- Life expectancy less than 1 year or severe neurologic outcome
- Unable or unwilling to give informed consent
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ICD-implantation
Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
|
Implantation of an ICD for secondary prevention
Other Names:
|
No Intervention: Standard care
Guideline directed medical therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 5 years
|
The clinical event committee will aim to attribute the cause of death to the underlying disease process rather than the immediate mechanism.
Mortality will be classified as cardiovascular and non-cardiovascular.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality
Time Frame: 1 year
|
1 year
|
|
Sudden cardiovascular death
Time Frame: 1 year
|
Cardiovascular death fulfilling the following criteria:
|
1 year
|
Cardiovascular death
Time Frame: 1 year
|
Mortality is considered as cardiovascular unless it is clearly attributable to another cause and thus includes:
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device revision or replacement due to infection or malfunction
Time Frame: 1 year
|
Explorative outcome
|
1 year
|
Appropriate shock from an ICD (successfully treated VT/VF)
Time Frame: 1 year
|
Explorative outcome
|
1 year
|
Inappropriate shock from an ICD (shock on non-VT/VF)
Time Frame: 1 year
|
Explorative outcome
|
1 year
|
Register-based all cause mortality
Time Frame: 10 years
|
10 years
|
|
Register-based sudden cardiovascular death
Time Frame: 5 years
|
5 years
|
|
Register-based sudden cardiovascular death
Time Frame: 10 years
|
10 years
|
|
Register-based cardiovascular death
Time Frame: 5 years
|
5 years
|
|
Register-based cardiovascular death
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Reza Jabbari, MD, PhD, Rigshospitalet, Denmark
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 12, 2020
Primary Completion (Estimated)
October 1, 2032
Study Completion (Estimated)
October 1, 2032
Study Registration Dates
First Submitted
September 29, 2020
First Submitted That Met QC Criteria
September 29, 2020
First Posted (Actual)
October 6, 2020
Study Record Updates
Last Update Posted (Estimated)
November 9, 2023
Last Update Submitted That Met QC Criteria
November 8, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Infarction
- Heart Arrest
- Myocardial Infarction
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Ventricular Fibrillation
- Tachycardia
- Tachycardia, Ventricular
- Out-of-Hospital Cardiac Arrest
Other Study ID Numbers
- H-20007332
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Implantable cardioverter defibrillator
-
Boston Scientific CorporationCompleted
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedHeart DiseasesUnited States
-
Boston Scientific CorporationCompleted
-
Population Health Research InstituteBoston Scientific CorporationCompleted
-
Medtronic Bakken Research CenterAstraZenecaCompletedAcute Myocardial InfarctionNetherlands
-
Rennes University HospitalCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedVentricular ArrhythmiasGermany, United States, Denmark, Canada, Netherlands, Switzerland, Austria
-
Maurizio Eugenio LandolinaRecruitingAppropriate and Inappropriate Shock Therapy With ICD | Arrhythmias DetectionItaly
-
Deutsches Herzzentrum MuenchenCompleted
-
Biotronik SE & Co. KGCompletedTachyarrhythmiaGermany, Switzerland